Jessica DeBenedetto, 43, has found a life-changing experience with compounded tirzepatide for weight loss, especially after struggles with prediabetes and weight gain. However, her optimism is dampened by the FDA's recent decision to phase out compounded versions, meaning only the pricier, FDA-approved options will remain. This poses a challenge for many in similar situations seeking affordable solutions for effective weight management. DeBenedetto is now considering a temporary switch to compounded semaglutide, but concerns linger about its future availability as well.
For now, her doctor is going to switch her over to compounded semaglutide - the active pharmaceutical ingredient in Ozempic and Wegovy, made by Novo Nordisk.
The FDA has removed the drug from its shortage list and set a timeline for pharmacies to stop making compounded versions of the drug.
Collection
[
|
...
]